Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

JDRF, BD To Develop Glucose Monitoring Devices For Type 1 Diabetes - Quick Facts

RELATED NEWS
Trade BDX now with 

JDRF and Becton, Dickinson and Co. or BD (BDX: Quote) extended their existing collaboration focused on Type 1 diabetes or T1D to accelerate the development of BD's proprietary glucose-sensing technology which has shown promise in providing very accurate and reliable continuous glucose information. JDRF and Helmsley Charitable Trust or HCT joined forces to support novel technologies that would be essential for developing fully automated artificial pancreas systems with advanced monitoring capabilities.

The research expansion is part of the JDRF-HCT Sensor Initiative designed to accelerate the development of advanced sensors that improve the detection of changing glucose levels.

"While we continue to search for the elusive cure, we must give people with T1D better tools to ease the burden of managing their disease, and this project is a step forward toward that goal," said David Panzirer, Trustee, The Helmsley Charitable Trust.

Click here to receive FREE breaking news email alerts for Becton, Dickinson and Company and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
A number of major retailers will be open on Thanksgiving for early Black Friday shopping events. Kohl's department stores will kick off Black Friday sales two hours earlier this year, at 6 p.m. Thanksgiving Day, while Macy's, Bon-Ton and Best Buy will open at the same time. J.C. Penney and Sears... Twitter Inc. has replaced its head of product Daniel Graf just six months after luring him over from Google, according to multiple reports. Graf, previously known for his work leading Google Maps, will retain his vice president of product title and work on Twitter's geolocation features, the Wall... LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that its third quarter loss widened slightly from last year, as higher costs and expenses more than offset a 45% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.